GW Pharmaceuticals PLC Presenting at Leerink Rare Disease Roundtable 2014 (4154S)

TIDMGWP

RNS Number : 4154S

GW Pharmaceuticals PLC

24 September 2014

GW Pharmaceuticals to Present at the Leerink Rare Disease Roundtable 2014

London, UK, 24 September 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Leerink Rare Disease Roundtable 2014 on Wednesday, 1 October, 2014 at 8:25 a.m. ET. The conference will be held at the Le Parker Meridian Hotel in New York City.

A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 26 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. This Phase 3 program has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) and is intended to support the submission of a New Drug Application for Sativex in cancer pain with the FDA and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex(R) in the treatment of childhood epilepsy, which has received Fast Track Designation from the FDA for Dravet syndrome as well as Orphan Drug Designations from the FDA in both the treatment of Dravet syndrome and Lennox-Gastaut syndrome. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

 
 GW Pharmaceuticals plc                        (Today) [phone] 
 Justin Gover, Chief Executive Officer         (Thereafter) + 44 1980 
                                                557000 
 Stephen Schultz, VP Investor Relations        917 280 2424 / 401 500 
  (U.S.)                                        6570 
 
 FTI Consulting (Media Enquiries) 
 Ben Atwell / Simon Conway / John Dineen 
  (UK)                                         + 44 20 3727 1000 
 Robert Stanislaro (U.S.)                      212 850 5657 
 
 Trout Group, LLC (U.S. investor relations) 
 Todd James / Chad Rubin                       646 378 2900 
 
 Peel Hunt LLP (UK NOMAD)                      [phone] 
 James Steel / Clare Terlouw 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCPGURABUPCGCW